A Rollover Protocol of Dacomitinib For Patients In Japan

• Status: Completed
• Trial end date: 2019-05-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study to permit continued access to dacomitinib for patients who participated in other dacomitinib monotherapy treatment protocols in Japan and have the potential to derive clinical benefit without unacceptable toxicity from continued dacomitinib treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:

• Patients who received dacomitinib on another clinical trial in Japan

• Evidence of a personally signed and dated informed consent document

Exclusion Criteria:

• Patients who meet one or more study withdrawal criteria on the prior study

• Participation in other studies involving other investigational drug(s) during study participation